Helene Hartvedt Grytli
Position: Post.Doc
Phone: +47 22 78 23 13
Email:
 

Author network for Helene Hartvedt Grytli by COREMINE medical


Publications 2017

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer (in press)
PubMed 28972967

Publications 2016

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-94
PubMed 26646591

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang WZ, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Maelandsmo GM, Svindland A, Barbier O, Tasken KA (2016)
Low beta(2)-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-1894

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS (2016)
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
Urol Oncol, 35 (3), 111.e1-111.e8
PubMed 27838142

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA (2016)
PBX3 is a putative biomarker of aggressive prostate cancer
Int J Cancer, 139 (8), 1810-20
PubMed 27273830

Publications 2014

Braadland PR, Ramberg H, Grytli HH, Taskén KA (2014)
β-Adrenergic Receptor Signaling in Prostate Cancer
Front Oncol, 4, 375
PubMed 25629002

Publications 2013

Grytli HH, Fagerland MW, Fosså SD, Taskén KA (2013)
Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's letter to the editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007
Eur Urol, 64 (1), e11-2
PubMed 23602404

Grytli HH, Fagerland MW, Fosså SD, Taskén KA (2013)
Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease
Eur Urol, 65 (3), 635-41
PubMed 23351721

Publications 2012

Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL (2012)
Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy
Prostate, 73 (3), 250-60
PubMed 22821802